NCT05562453View on ClinicalTrials.gov

Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain

NAUnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

July 15, 2023

Study Completion Date

August 15, 2023

Conditions
Multiple SclerosisSpasticity, MusclePain, Chronic
Interventions
DEVICE

FlowOx 2.0

Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.

DEVICE

FlowOx2.0 (Sham)

Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.

Trial Locations (1)

113 65

NeuroCentrum (Centrum för Neurologi), Stockholm

Sponsors

Lead Sponsor

Otivio AS
All Listed Sponsors
lead

Otivio AS

INDUSTRY